Allarity Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. (ticker: ALLR) is a United States-based clinical-stage biopharmaceutical company listed on NASDAQ. The company’s strategy is built around precision oncology: it develops cancer therapies alongside its proprietary Drug Response Predictor (DRP®) platform, which is intended to identify the patients most likely to benefit from a given therapy. In practical terms, Allarity is trying to improve clinical success rates by better matching drug and patient, rather than by relying on broad, one-size-fits-all oncology development. Allarity traces its origins to Denmark. According to company disclosures, the business was founded in 2004 as Medical Prognosis Institute A/S, with foundational work led by Steen Knudsen, Ph.D., and Thomas H. Jensen around bioinformatics and diagnostic approaches aimed at improving cancer treatment response. The company later restructured and became Allarity Therapeutics. Today, its corporate headquarters are in Boston, Massachusetts, while it maintains an R&D presence in Hørsholm, Denmark. That transatlantic footprint reflects both its U.S. public-market base and its European scientific roots. From a business-line perspective, Allarity is primarily focused on stenoparib (2X-121), a differentiated dual PARP and WNT/Tankyrase pathway inhibitor being developed for difficult-to-treat cancers, especially advanced recurrent ovarian cancer. The company also advances companion diagnostic capabilities built on its DRP® technology, which it uses to support patient selection in clinical trials and, in theory, to enhance both efficacy and development efficiency. This places Allarity in a highly competitive oncology biotech niche where differentiation depends on clinical data, biomarker validation, and access to capital. Its market position is that of a small-cap, high-risk, data-driven oncology developer rather than a diversified pharmaceutical platform. The competitive set includes other precision oncology and PARP-focused companies, but Allarity’s main differentiator is the combination of stenoparib plus DRP-guided enrollment. The company has also referenced additional exploratory work in cancers beyond ovarian, including small cell lung cancer and colorectal cancer, although stenoparib remains the core asset. Recent developments have been important. In 2025 and 2026, Allarity reported ongoing Phase 2 activity, including updated clinical data presented at major scientific meetings such as AACR and SGO, and it received FDA Fast Track designation for stenoparib in advanced ovarian cancer. In March 2026, the company announced approximately $20 million in non-convertible debt financing, which it said would support completion of Phase 2 work, regulatory preparation, and progress toward a potential pivotal trial. For investors, ALLR remains a speculative NASDAQ-listed oncology story in the United States, with value creation heavily tied to clinical execution, regulatory milestones, and the eventual validation of its DRP®-guided development model.